Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461) - Byrd,J.C.; Mrozek,K.; Dodge,R.K. (Blood, 2002)